|
1
|
Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2.
|
PLoS Biol
|
2009
|
9.63
|
|
2
|
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma.
|
Cancer Cell
|
2006
|
6.15
|
|
3
|
T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR.
|
Proc Natl Acad Sci U S A
|
2008
|
5.97
|
|
4
|
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases.
|
Nat Chem Biol
|
2008
|
3.84
|
|
5
|
A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma.
|
Cancer Res
|
2007
|
2.62
|
|
6
|
Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha.
|
Cancer Cell
|
2008
|
2.32
|
|
7
|
PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.
|
Cancer Res
|
2008
|
2.20
|
|
8
|
To stabilize neutrophil polarity, PIP3 and Cdc42 augment RhoA activity at the back as well as signals at the front.
|
J Cell Biol
|
2006
|
2.10
|
|
9
|
A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition.
|
Biochem J
|
2008
|
1.96
|
|
10
|
EGFR signals to mTOR through PKC and independently of Akt in glioma.
|
Sci Signal
|
2009
|
1.66
|
|
11
|
Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach.
|
Blood
|
2009
|
1.58
|
|
12
|
Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.
|
J Clin Invest
|
2008
|
1.56
|
|
13
|
Phosphatidylinositol 4-kinase IIIbeta regulates the transport of ceramide between the endoplasmic reticulum and Golgi.
|
J Biol Chem
|
2006
|
1.52
|
|
14
|
HIV-1 Nef assembles a Src family kinase-ZAP-70/Syk-PI3K cascade to downregulate cell-surface MHC-I.
|
Cell Host Microbe
|
2007
|
1.26
|
|
15
|
Characterization of structurally distinct, isoform-selective phosphoinositide 3'-kinase inhibitors in combination with radiation in the treatment of glioblastoma.
|
Mol Cancer Ther
|
2008
|
1.16
|
|
16
|
Targeting the gatekeeper residue in phosphoinositide 3-kinases.
|
Bioorg Med Chem
|
2005
|
1.13
|
|
17
|
Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi's sarcoma.
|
Cancer Res
|
2008
|
1.08
|
|
18
|
Design of drug-resistant alleles of type-III phosphatidylinositol 4-kinases using mutagenesis and molecular modeling.
|
Biochemistry
|
2008
|
1.06
|
|
19
|
Discovery of dual inhibitors of the immune cell PI3Ks p110delta and p110gamma: a prototype for new anti-inflammatory drugs.
|
Chem Biol
|
2010
|
1.05
|
|
20
|
Genetic or pharmaceutical blockade of p110delta phosphoinositide 3-kinase enhances IgE production.
|
J Allergy Clin Immunol
|
2008
|
1.00
|
|
21
|
Effect of combined DNA repair inhibition and G2 checkpoint inhibition on cell cycle progression after DNA damage.
|
Mol Cancer Ther
|
2006
|
0.93
|
|
22
|
Activity of the p110-alpha subunit of phosphatidylinositol-3-kinase is required for activation of epithelial sodium transport.
|
Am J Physiol Renal Physiol
|
2008
|
0.88
|
|
23
|
Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.
|
J Clin Invest
|
2017
|
0.75
|